Eriksson Tuula M, Day Richard M, Fedele Stefano, Salih Vehid M
Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, University College London, London, UK.
Applied Biomedical Engineering, Division of Medicine, University College London, London, UK.
J Tissue Eng. 2016 Sep 29;7:2041731416669629. doi: 10.1177/2041731416669629. eCollection 2016 Jan-Dec.
Ameloblastoma is a rare, odontogenic neoplasm with benign histopathology, but extensive, local infiltrative capacity through the bone tissue it originates in. While the mechanisms of ameloblastoma invasion through the bone and bone absorption are largely unknown, recent investigations have indicated a role of the osteoprotegerin/receptor activator of nuclear factor kappa-B ligand regulatory mechanisms. Here, we present results obtained using a novel in vitro organotypic tumour model, which we have developed using tissue engineering techniques. Using this model, we analysed the expression of genes involved in bone turnover and detected a 700-fold increase in receptor activator of nuclear factor kappa-B ligand levels in the co-culture models with ameloblastoma cells cultured with bone cells. The model described here can be used for gene expression studies, as a basis for drug testing or for a more tailored platform for testing of the behaviour of different ameloblastoma tumours in vitro.
成釉细胞瘤是一种罕见的牙源性肿瘤,组织病理学上为良性,但对其起源的骨组织具有广泛的局部浸润能力。虽然成釉细胞瘤侵袭骨组织和骨吸收的机制尚不清楚,但最近的研究表明骨保护素/核因子κB受体激活剂配体调节机制发挥了作用。在此,我们展示了使用新型体外器官型肿瘤模型获得的结果,该模型是我们利用组织工程技术构建的。利用该模型,我们分析了参与骨转换的基因表达,并在成釉细胞瘤细胞与骨细胞共培养的模型中检测到核因子κB受体激活剂配体水平增加了700倍。本文所述模型可用于基因表达研究,作为药物测试的基础,或作为一个更具针对性的平台,用于体外测试不同成釉细胞瘤肿瘤的行为。